Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Atlanta, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Rimidi, a market-leading digital health company that supports healthcare providers with EHR-integrated software, services, and connected devices, recently...
-
Chicago, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The global diagnostic ultrasound market was valued at US$ 8.4 billion in 2024 and is expected to reach 12.4 billion by 2033, growing at a CAGR of 4.4%...
-
TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
-
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- DarkPulse, Inc. (OTCQB: DPLS) (“DarkPulse” or the “Company”), a leader in advanced distributed fiber optic sensing technology for critical infrastructure...
-
All initial drill holes intersect continuous rare earth mineralization in weathered clays from surface and were still in mineralization at end of holeBest intercept: 14.2 metres from surface averaging...
-
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data...
-
Continued organic quarter over quarter revenue growth despite expected summer seasonalityEarnings per share for Q3, 2025: ($0.05) per share.Oversubscribed raise of C$4.23m contributing to...
-
This is the first agreement signed by the EIB with a corporate venture capital in the healthcare sector, and is part of the EU strategy to support the development of innovative companies across the...
-
KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”) today announced that it has executed an Exclusive Intellectual Property License Agreement for...
-
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...